Sources | Names Used |
---|---|
CTRPv2 | sirolimus:bortezomib (250:1 mol/mol) |
PharmacoGx | sirolimus:bortezomib (250:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ACTN1 | CTRPv2 | pan-cancer | AAC | -0.15 | 0.0001 |
mRNA | BTD | CTRPv2 | pan-cancer | AAC | -0.15 | 8e-05 |
mRNA | TOR4A | CTRPv2 | pan-cancer | AAC | -0.15 | 7e-05 |
mRNA | VANGL1 | CTRPv2 | pan-cancer | AAC | -0.14 | 4e-05 |
mRNA | SNX33 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0002 |
mRNA | SLC16A3 | CTRPv2 | pan-cancer | AAC | -0.14 | 7e-05 |
mRNA | OR2L5 | CTRPv2 | pan-cancer | AAC | -0.14 | 3e-05 |
mRNA | TESMIN | CTRPv2 | pan-cancer | AAC | -0.14 | 3e-05 |
mRNA | RASAL2 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0002 |
mRNA | MYO1F | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0001 |